image
Healthcare - Medical - Devices - NASDAQ - US
$ 145.74
0.144 %
$ 4.65 B
Market Cap
-46.41
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one IRTC stock under the worst case scenario is HIDDEN Compared to the current market price of 146 USD, iRhythm Technologies, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one IRTC stock under the base case scenario is HIDDEN Compared to the current market price of 146 USD, iRhythm Technologies, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one IRTC stock under the best case scenario is HIDDEN Compared to the current market price of 146 USD, iRhythm Technologies, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart IRTC

image
$150.0$150.0$140.0$140.0$130.0$130.0$120.0$120.0$110.0$110.0$100.0$100.0$90.0$90.0$80.0$80.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
592 M REVENUE
20.13%
-116 M OPERATING INCOME
7.71%
-113 M NET INCOME
100.00%
3.39 M OPERATING CASH FLOW
106.77%
-123 M INVESTING CASH FLOW
-10072.29%
511 M FINANCING CASH FLOW
5697.97%
159 M REVENUE
-3.44%
-32.6 M OPERATING INCOME
-697.35%
-30.7 M NET INCOME
-2203.08%
-7.89 M OPERATING CASH FLOW
-41.03%
-38.1 M INVESTING CASH FLOW
68.78%
1.73 M FINANCING CASH FLOW
-42.12%
Balance Sheet iRhythm Technologies, Inc.
image
Current Assets 646 M
Cash & Short-Term Investments 536 M
Receivables 79.9 M
Other Current Assets 30.3 M
Non-Current Assets 286 M
Long-Term Investments 61.9 M
PP&E 173 M
Other Non-Current Assets 51.1 M
57.50 %8.58 %3.26 %6.65 %18.54 %5.48 %Total Assets$931.4m
Current Liabilities 111 M
Accounts Payable 7.22 M
Short-Term Debt 15.9 M
Other Current Liabilities 87.8 M
Non-Current Liabilities 730 M
Long-Term Debt 646 M
Other Non-Current Liabilities 83.2 M
10.45 %76.91 %9.90 %Total Liabilities$840.5m
EFFICIENCY
Earnings Waterfall iRhythm Technologies, Inc.
image
Revenue 592 M
Cost Of Revenue 184 M
Gross Profit 408 M
Operating Expenses 523 M
Operating Income -116 M
Other Expenses -2.22 M
Net Income -113 M
600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)592m(184m)408m(523m)(116m)2m(113m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
68.86% GROSS MARGIN
68.86%
-19.52% OPERATING MARGIN
-19.52%
-19.14% NET MARGIN
-19.14%
-124.62% ROE
-124.62%
-12.16% ROA
-12.16%
-13.88% ROIC
-13.88%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis iRhythm Technologies, Inc.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)(70m)(70m)(80m)(80m)(90m)(90m)(100m)(100m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -113 M
Depreciation & Amortization 25.8 M
Capital Expenditures -33.9 M
Stock-Based Compensation 0
Change in Working Capital 0
Others 3.39 M
Free Cash Flow -30.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets iRhythm Technologies, Inc.
image
Wall Street analysts predict an average 1-year price target for IRTC of $114 , with forecasts ranging from a low of $78 to a high of $146 .
IRTC Lowest Price Target Wall Street Target
78 USD -46.48%
IRTC Average Price Target Wall Street Target
114 USD -21.49%
IRTC Highest Price Target Wall Street Target
146 USD 0.18%
Price
Max Price Target
Min Price Target
Average Price Target
15015014014013013012012011011010010090908080707060605050Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 10
6. Ownership
Insider Ownership iRhythm Technologies, Inc.
image
Sold
0-3 MONTHS
1.65 M USD 4
3-6 MONTHS
10.1 M USD 8
6-9 MONTHS
1.46 M USD 2
9-12 MONTHS
521 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
501 K USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
DOCS vs. IRTC: Who Will Win High-Stakes AI Showdown in Digital Health? DOCS and IRTC are redefining digital health with AI, but only one is winning big with investors in 2025's market surge. zacks.com - 1 week ago
Robbins LLP Informs iRhythm Technologies, Inc. (IRTC) Investors That the Class Action Beat the Motion to Dismiss iRhythm misled investors by promoting Zio AT as a real-time monitor for high-risk patients, inflating stock prices that dropped when the truth emerged. globenewswire.com - 1 week ago
iRhythm Technologies, Inc. (NASDAQ: IRTC) Investor Alert: Schubert Jonckheer & Kolbe LLP Investigating Possible Shareholder Claims for False Statements and Insider Trading SAN FRANCISCO , June 17, 2025 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP advises iRhythm Technologies, Inc. investors that the firm is investigating potential legal claims relating to alleged false statements exaggerating the capabilities of iRhythm's wearable Zio AT heart event monitor. Current shareholders are encouraged to contact the firm. prnewswire.com - 1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Investors to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 1 week ago
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Connect NEW YORK CITY, NY / ACCESS Newswire / June 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating iRhythm Technologies, Inc. (IRTC) And Encourages Stockholders to Connect NEW YORK CITY, NY / ACCESS Newswire / June 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 2 weeks ago
iRhythm Technologies, Inc. (IRTC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against iRhythm Technologies, Inc. (IRTC) and Encourages Stockholders to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against iRhythm Technologies, Inc. (IRTC) And Encourages Investors to Reach Out NEW YORK CITY, NY / ACCESS Newswire / May 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of iRhythm Technologies, Inc. ("iRhythm" or "the Company") (NASDAQ:IRTC). Investors who purchased iRhythm securities prior to January 11, 2022, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/IRTC. accessnewswire.com - 1 month ago
iRhythm Technologies to Participate in Upcoming Investor Conferences SAN FRANCISCO, May 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is scheduled to present at the following investor conferences. globenewswire.com - 1 month ago
Zio Demand Drives 20% Revenue Growth For iRhythm, Bullish Sentiment Builds Among Analysts iRhythm Technologies Inc IRTC on Thursday reported first quarter 2025 revenue of $158.7 million, up 20.3% year over year, beating the consensus of $153.38 million. benzinga.com - 1 month ago
8. Profile Summary

iRhythm Technologies, Inc. IRTC

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 4.65 B
Dividend Yield 0.00%
Description iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that combines a wire-free, patch-based, and wearable biosensor with a cloud-based data analytic platform to help physicians to monitor patients and diagnose arrhythmias. The company's Zio XT and AT monitors, a single-use, wire-free, and wearable patch-based biosensors, records patient's heartbeats and ECG data. It has a development collaboration agreement with Verily Life Sciences LLC to develop various next-generation atrial fibrillation screening, detection, or monitoring products. The company was incorporated in 2006 and is headquartered in San Francisco, California.
Contact 699 8th Street, San Francisco, CA, 94103 https://www.irhythmtech.com
IPO Date Oct. 20, 2016
Employees 2000
Officers Mr. Daniel G. Wilson Chief Financial Officer, Principal Financial Officer, EVice President of Corporate Development & Investor Relations Dr. Minang P. Turakhia M.D., M.S. Chief Medical & Scientific Officer and Executive Vice President of Product Innovation Mr. Mervin Smith Executive Vice President of Business Operations Mr. Marc Rosenbaum Senior Vice President of Finance & Chief Accounting Officer Mr. Patrick Michael Murphy J.D. Chief Business & Legal Officer Ms. Sumi Shrishrimal Executive Vice President & Chief Risk Officer Mr. Chad M. Patterson Chief Commercial Officer Mr. Quentin S. Blackford President, Chief Executive Officer & Director Mr. Brian Lawrence Executive Vice President & Chief Technology Officer Ms. Stephanie Zhadkevich Director of Investor Relations